Development of ploidy and cell proliferation in serial samples of ascites from patients with ovarian carcinoma

Other OA: gold public-domain-us
⚙ AI-generated summary by qwen3.7-flash, 2026-10-08 ⓘ

Analysis of serial ascites samples from 14 ovarian carcinoma patients revealed that while ploidy remained stable, S-phase proportions increased significantly over time, suggesting a shift toward more aggressive tumor cell lines and chemoresistance.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-08 · read from full text ⓘ

This study analyzed serial ascites samples from 14 ovarian carcinoma patients to track changes in tumor cell ploidy and proliferation over periods ranging from 10 to 360 days. Using flow cytometry and monoclonal antibodies for bromodeoxyuridine labeling, the researchers found that while ploidy remained largely stable, the proportion of cells in the S-phase increased significantly over time. The authors suggest this rise in proliferation reflects selective pressures favoring more aggressive tumor cell lines and the development of chemoresistance. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Repeated samples of ascites were obtained from 14 ovarian carcinoma patients over a period of 10 to 360 days. The samples were studied by means of flow-cytometry and monoclonal antibodies specific for bromodeoxyuridine. Ploidy and proliferation of tumor cell populations were measured to establish the significance of these properties in the development of the tumors. Ploidy was mostly a stable feature while the proportion of S-phase values increased significantly over the passage of time. This increase is discussed in relation to the expression of selective processes towards more aggressive tumor cell lines and to the development of chemoresistance.
Full text 936 characters · extracted from oa-html · click to expand
Development of Ploidy and Cell Proliferation in Serial Samples of Ascites from Patients with Ovarian Carcinoma DOI: https://doi.org/10.3109/02841869009126544Keywords: Ovarian carcinoma, ascites, flow-cytometry, Brd-Urd labelling index, ploidy, proliferation, chemotherapyAbstract Repeated samples of ascites were obtained from 14 ovarian carcinoma patients over a period of 10 to 360 days. The samples were studied by means of flow-cytometry and monoclonal antibodies specific for bromodeoxyuridine. Ploidy and proliferation of tumor cell populations were measured to establish the significance of these properties in the development of the tumors. Ploidy was mostly a stable feature while the proportion of S-phase values increased significantly over the passage of time. This increase is discussed in relation to the expression of selective processes towards more aggressive tumor cell lines and to the development of chemoresistance.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma Endometriosis Ovarian Neoplasms Ploidies Ploidies Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adult Adult Aged Aged Ascites Ascites Ascites Bromodeoxyuridine Bromodeoxyuridine Bromodeoxyuridine Cell Division

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-11-01T09:25:17.647243+00:00
pubmed
last seen: 2026-10-08T21:11:19.299510+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine